Patents by Inventor Martin JEFSON

Martin JEFSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
    Publication number: 20230287093
    Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.
    Type: Application
    Filed: January 17, 2023
    Publication date: September 14, 2023
    Applicant: Pinteon Therapeutics Inc.
    Inventors: Shankar Kumar, Naoya Tsurushita, Michael Ahlijanian, Martin Jefson
  • Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
    Patent number: 11591385
    Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: February 28, 2023
    Assignee: Pinteon Therapeutics Inc.
    Inventors: Shankar Kumar, Naoya Tsurushita, Michael Ahlijanian, Martin Jefson
  • METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
    Publication number: 20200362022
    Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.
    Type: Application
    Filed: November 8, 2018
    Publication date: November 19, 2020
    Applicant: Pinteon Therapeutics Inc.
    Inventors: Shankar KUMAR, Naoya Tsurushita, Michael Ahlijanian, Martin JEFSON